Cynata Therapeutics (CYYNF) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free CYYNF Stock Alerts $0.11 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartStock AnalysisChart All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative March 6, 2024 | msn.comCynata Therapeutics treats first patient in aGvHD drug trialMarch 4, 2024 | finance.yahoo.comFirst Patient Treated in Phase 2 GvHD TrialAugust 14, 2023 | markets.businessinsider.comVYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 11, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and Vor Biopharma (VOR)August 10, 2023 | technews.tmcnet.comTScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 19, 2023 | benzinga.comCyteir Therapeutics 10% Owner Sold $106K In Company StockMay 2, 2023 | finance.yahoo.comDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorNovember 16, 2022 | finance.yahoo.comWe Think Shareholders Are Less Likely To Approve A Pay Rise For Cynata Therapeutics Limited's (ASX:CYP) CEO For NowNovember 4, 2022 | finance.yahoo.comLUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney TransplantationSeptember 26, 2022 | benzinga.comCynata Therapeutics Stock (OTC:CYYNF), Earnings Estimates, EPS, and RevenueMay 26, 2022 | finance.yahoo.comUS FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHDJanuary 14, 2022 | finance.yahoo.comWe Think Cynata Therapeutics (ASX:CYP) Can Afford To Drive Business GrowthDecember 29, 2021 | msn.comHere’s why the Cynata (ASX:CYP) share price is rising todaySeptember 30, 2021 | finance.yahoo.comCynata Enters into a New Strategic Partnership with Fujifilm Get Cynata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here CYYNF Media Mentions By Week CYYNF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYYNF News Sentiment▼0.000.54▲Average Medical News Sentiment CYYNF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYYNF Articles This Week▼00▲CYYNF Articles Average Week Get Cynata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TVGN News Today NRSN News Today OTLC News Today GCTK News Today MTEX News Today EDSA News Today NERV News Today PMD News Today SNTI News Today TLIS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYYNF) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsA ‘DeFi Summer’ Projected!Crypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsUrgent Nvidia WarningAltimetryBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
